Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,835 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, Kaufman D, Ligueros-Saylan M, Howard M, Zhu R, Owen R, Wong K, Islam L, Bachert C. Gevaert P, et al. Among authors: zhu r. J Allergy Clin Immunol. 2020 Sep;146(3):595-605. doi: 10.1016/j.jaci.2020.05.032. Epub 2020 Jun 7. J Allergy Clin Immunol. 2020. PMID: 32524991 Free article. Clinical Trial.
Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial.
Braithwaite IE, Cai F, Tom JA, Galanter JM, Owen RP, Zhu R, Williams M, McGregor AG, Eliahu A, Durk MR, Dengler HS, Zak M, Kenny JR, Wilson ME, Beasley R, Chen H. Braithwaite IE, et al. Among authors: zhu r. J Allergy Clin Immunol. 2021 Sep;148(3):783-789. doi: 10.1016/j.jaci.2021.02.042. Epub 2021 Mar 17. J Allergy Clin Immunol. 2021. PMID: 33744327 Free article. Clinical Trial.
Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC-0214 in healthy volunteers.
Zhu R, Chen H, Galanter J, She G, Cai F, Durk MR, Zou Y, Chen L, Kenny JR, Vadhavkar S, Warren S, Taylor G, Hwang O, Eliahu A, Wynne C, Owen R. Zhu R, et al. Clin Transl Sci. 2022 May;15(5):1225-1237. doi: 10.1111/cts.13240. Epub 2022 Feb 26. Clin Transl Sci. 2022. PMID: 35157370 Free PMC article. Clinical Trial.
A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma.
Harris JM, Maciuca R, Bradley MS, Cabanski CR, Scheerens H, Lim J, Cai F, Kishnani M, Liao XC, Samineni D, Zhu R, Cochran C, Soong W, Diaz JD, Perin P, Tsukayama M, Dimov D, Agache I, Kelsen SG. Harris JM, et al. Among authors: zhu r. Respir Res. 2016 Mar 18;17:29. doi: 10.1186/s12931-016-0347-2. Respir Res. 2016. PMID: 26993628 Free PMC article. Clinical Trial.
Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires.
Svensson RJ, Ribbing J, Kotani N, Dolton M, Vadhavkar S, Cheung D, Staton T, Choy DF, Putnam W, Jin J, Budha N, Karlsson MO, Quartino A, Zhu R. Svensson RJ, et al. Among authors: zhu r. CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1221-1235. doi: 10.1002/psp4.12690. Epub 2021 Aug 5. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34346168 Free PMC article. Clinical Trial.
Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation.
Chen H, Kunder R, Zou Y, Staton T, Zhu R, Galanter J, Gugelmann H, Owen R, Grimbaldeston MA, Chang JK, Durk MR, Eliahu A, Wilson MS, Choy DF, Wilson M, Black M, Doppen M, Kung S, Oldfield K, Sparks J, Beasley R, Braithwaite I. Chen H, et al. Among authors: zhu r. Pulm Pharmacol Ther. 2022 Aug;75:102133. doi: 10.1016/j.pupt.2022.102133. Epub 2022 May 26. Pulm Pharmacol Ther. 2022. PMID: 35644305 Clinical Trial.
5,835 results